Awards

$497K

Cryopreservation of Anopheles Embryos

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 08/01/16 - 07/31/17
PI: Peter F. Billingsley

DESCRIPTION (provided by applicant): The ideal, most effective, tool for eliminating Plasmodium falciparum (Pf), the causative agent of 99% of all malaria deaths, is a highly effective vaccine that prevents blood stage infection and thereby prevents both disease and transmission. Sanaria's goal is to develop and commercialize a Pf sporozoite (SP...

$1MM

A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with a live attenuated sporozoite malaria vaccine

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 06/16/16 - 05/31/17
PI: Stephen Lev Hoffman

? DESCRIPTION (provided by applicant): The world needs a highly effective malaria vaccine. Sanaria(r) PfSPZ Vaccine, composed of aseptic, purified, cryopreserved radiation attenuated PfSPZ, protected 100% of volunteers in an NIH clinical trial. The vaccine has been administered by direct venous inoculation (DVI) to 371 subjects in Mali, Tanza...

$989K

Universal Attenuated Sporozoite Vaccine and Challenge System

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 06/15/16 - 05/31/17
PI: Stephen Lev Hoffman

ABSTRACTSanaria?s Plasmodium falciparum (Pf) sporozoite (SPZ) vaccines development program is receiving globalsupport. Trials of PfSPZ Vaccine (radiation attenuated PfSPZ) or PfSPZ-CVac (PfSPZ ChemoprophylaxisVaccine) administered by direct venous inoculation (DVI), including ~1,500 adults to infants were initiated inDecember 2015 (Tanzania, U.S...

$300K

Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites (PvSPZ Challenge) for controlled human malaria infection (CHMI)

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 04/21/16 - 03/31/17
PI: Stephen Lev Hoffman

? DESCRIPTION (provided by applicant): Plasmodium vivax (Pv), the second most important human malaria parasite, causes more than 80 million cases annually including severe, fatal disease. Prevention and control are challenged by emerging drug resistance and relapses from dormant liver stage parasites called hypnozoites. The only therapy again...

$313K

Development of a whole parasite Plasmodium falciparum sexual and mosquito stages Vaccine to Interrupt Malaria Transmission

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 02/01/16 - 01/31/17
PI: Peter F. Billingsley

? DESCRIPTION (provided by applicant): This proposal will demonstrate proof of concept for a whole parasite (WP) vaccine directed against Plasmodium falciparum (Pf) sexual and mosquito stages (SMS) that will be used alone or in combination with PfSPZ Vaccine for interrupting malaria transmission (VIMT) from the human host to the mosquito vec...

$1000K

In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 01/01/16 - 12/31/16
PI: Stephen Lev Hoffman

? DESCRIPTION (provided by applicant): Sanaria's platform technology is production of aseptic, purified, cryopreserved Plasmodium falciparum (Pf) sporozoites (SPZ). This technology has produced three products administered by needle and syringe, all of which are in clinical trials - PfSPZ Vaccine (radiation attenuated PfSPZ), PfSPZ Challenge (...

$1000K

Genetically Attenuated PfSPZ Malaria Vaccine

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 01/01/16 - 12/31/16
PI: Stephen Lev Hoffman

? DESCRIPTION (provided by applicant): We build on the successful work in Phase II SBIR 5R43AI069631-02 in which a genetically attenuated Plasmodium falciparum (Pf) parasite (GAP) was produced and shown to generate aseptic Pf sporozoites (SPZ) that invade hepatocytes, but do not replicate. We will use this genetically attenuated double-mutant...

$1000K

Plasmodium Falciparum Whole Sporozoite Malaria Vaccine

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 08/01/15 - 07/31/16
PI: Stephen Lev Hoffman

DESCRIPTION (provided by applicant): The ideal tool for eliminating Plasmodium falciparum (Pf), the causative agent of 99% of all malaria deaths, would be a highly effective vaccine that prevents blood stage infection and thereby prevents the disease and transmission. The only immunogens demonstrated able to induce > 90%, sustained (10-28 months...

$981K

Cryopreservation of Anopheles Embryos

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 08/01/15 - 07/31/16
PI: Peter F. Billingsley

DESCRIPTION (provided by applicant): The ideal, most effective, tool for eliminating Plasmodium falciparum (Pf), the causative agent of 99% of all malaria deaths, is a highly effective vaccine that prevents blood stage infection and thereby prevents both disease and transmission. Sanaria's goal is to develop and commercialize a Pf sporozoite (SP...

$301K

Development of a whole parasite Plasmodium falciparum sexual and mosquito stages Vaccine to Interrupt Malaria Transmission

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 02/18/15 - 01/31/16
PI: Peter F. Billingsley

DESCRIPTION (provided by applicant): This proposal will demonstrate proof of concept for a whole parasite (WP) vaccine directed against Plasmodium falciparum (Pf) sexual and mosquito stages (SMS) that will be used alone or in combination with PfSPZ Vaccine for interrupting malaria transmission (VIMT) from the human host to the mosquito vector. ...

Load More